Irinotecan activates anti-tumor immunity in CT26 subcutaneous tumors

Topoisomerase I (Top1) is a classical drug target for anticancer therapy, but its role in immune signaling in cancer cells remain unclear. Here, we aimed to explore the possible role and mechanism of Irinotecan (CPT-11) in anti-tumor immunity. Overall design: CT26 subcutaneous tumors mRNA profiles of Control and CPT-11 tretment mice were generated by deep sequencing, in duplicate.